Wedbush Predicts Lower Earnings for Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Analysts at Wedbush cut their Q1 2025 earnings estimates for Xenon Pharmaceuticals in a research report issued on Thursday, January 23rd. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings per share of ($0.87) for the quarter, down from their prior forecast of ($0.84). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.13) per share. Wedbush also issued estimates for Xenon Pharmaceuticals’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.94) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($3.68) EPS, FY2026 earnings at ($4.23) EPS, FY2027 earnings at ($3.43) EPS and FY2028 earnings at $1.42 EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same quarter in the prior year, the firm earned ($0.73) EPS.

Other research analysts have also issued reports about the company. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Raymond James reiterated an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $56.00.

Xenon Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:XENE opened at $40.00 on Monday. The company has a market cap of $3.05 billion, a price-to-earnings ratio of -14.18 and a beta of 1.20. The business has a 50 day moving average price of $40.23 and a 200 day moving average price of $40.82. Xenon Pharmaceuticals has a twelve month low of $35.53 and a twelve month high of $50.99.

Insiders Place Their Bets

In related news, Director Gary Patou sold 4,891 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total transaction of $200,922.28. Following the completion of the transaction, the director now owns 23,573 shares in the company, valued at $968,378.84. This trade represents a 17.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Insiders have sold 62,383 shares of company stock worth $2,535,891 over the last 90 days. Corporate insiders own 5.52% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Blue Trust Inc. boosted its stake in shares of Xenon Pharmaceuticals by 174.7% in the 3rd quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 641 shares in the last quarter. Avior Wealth Management LLC bought a new position in Xenon Pharmaceuticals during the 4th quarter valued at about $101,000. nVerses Capital LLC acquired a new position in Xenon Pharmaceuticals in the third quarter valued at about $102,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 487 shares during the last quarter. Finally, KBC Group NV increased its holdings in shares of Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.